Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
BNP predictor de mortalidad cardiovascular en pacientes con enfermedad renal crónica terminal
Resumen
Introducción: la mortalidad por enfermedad cardiovascular (ECV) en pacientes con enfermedad renal crónica (ERC) es alta. En la población con ERC terminal (ERCT) la mortalidad es hasta 20 veces mayor en comparación a la población general. Los péptidos natriuréticos, especialmente el péptido natriurético tipo-B (BNP), han sido estudiados como posibles marcadores de riesgo de mortalidad por ECV. El objetivo de este trabajo es determinar si el BNP actúa como un marcador pronóstico para mortalidad por ECV en pacientes con ERCT.
Métodos: se estudiaron 53 pacientes con ERCT prevalentes en diálisis peritoneal sin evidencia clínica de insuficiencia cardiaca al inicio del estudio. El impacto de las variables se realizó con el modelo de regresión lineal. La probabilidad de sobrevida fue estimada con el análisis de Kaplan-Meier y la diferencia entre grupos con el test de Log-Rank, acorde a los niveles de BNP dividido en tertiles. La asociación de riesgo fue calculada con el análisis proporcional de Cox ajustado.
Resultados: el BNP fuertemente predice la mortalidad por ECV. El modelo de regresión de Cox mostró que el BNP es un predictor de muerte por ECV. Pacientes con niveles altos de BNP tuvieron mayor riesgo de muerte. Varios mecanismos fisiopatológicos no bien definidos están involucrados.
Conclusiones: el BNP predice la mortalidad por ECV en pacientes con ERCT. La medición sérica de este péptido puede ser útil para la estratificación de riesgo en estos pacientes y ajustar el plan terapéutico.
Palabras clave
Referencias
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU et al. Chronic kidney disease as a global public health problem: Approaches and initiatives - A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247-59.
Amato D, Alvarez-Aguilar C, Castañeda-Limones R, Rodríguez E, Ávila- Díaz M, Arreola F et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney Int. 2005;(Suppl):97:S11-S17.
Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What to we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract. 2005;101:47-52.
Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008:4:672-81.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension. 2003;42:1050-6.
Valocikova I, Kristofova B, Valocik G. Cardiac Biomarkers and chronic kidney disease. Bratisl Lek Listy. 2008;109:341-4.
Arici M, Walls J. End-stage renal disease, atherosclerosis and cardiovascular mortality: Is C-reactive protein the missing link?. Kidney Int. 2001;59:407-14.
Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ et al. IL haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006;17(3):863-70.
Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005;16(Suppl 1):S83-S88.
Joffy S, Rossner MH. Natriuretic peptides in ESRD. Am J Kidney Dis. 2005;46:1-10.
Cardarelli R, Lumicao TG. B-type natriuretic peptide: A review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. J Am Board Fam Pract. 2003;16:327-33.
Winkler K, Wanner Ch, Dreschsler Ch, Lilienthal J, März W, Krane V. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic patients. European Heart Journal. 2008;29:2092-9.
Jiménez-Navarro M, Jiménez DJ, Otero RM, Minguell RE, Cubero SJ, Bonet AL et. al. Utilidad de los péptidos natriuréticos en la insuficiencia cardiaca. Med Clin. 2008;130:591-6.
Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E et al. Augmented secretion brain natriuretic paptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991;180:431-6.
Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K-I, Akioka K et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992;92:29-34.
Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996;28:22-30.
Cataliotti A, Malatino LS, Jaugasaki M, Zoccali C, Castellino P, Giocone G et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clinic Proc. 2001;76:1111-9.
Baubek N, Akay H, Altay M, Uz E, Turgut F, Uyar ME et al. Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int. 2007;27:663-8.
Devereux RB, Alonso DR, Lutas M, Gottlieb GJ, Sachs I, Reicheck N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-8.
Ganau A, Saba PS, Roman MJ, de Simone G, Realdi G, Devereux RB. Ageing induces left ventricular remodeling in normotensive subjects. J Hypertens. 1995;13:1818-22.
Zoccali C, Mallanaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508-1515.
Cataliotti A, Malatino LS, Jougasali M, Zoccali C, Castellino P, Giocone G et al. Circulating natriuretic peptide concentration in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker of ventricular remodeling. Mayo Clinic Proc. 2001;76:1111-1119.
Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007;71:548-54.
Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R et al. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: Results from the ADEMEX trial. Clin J Am Soc Nephrol. 2008;3:407-15.
London GM, Guerin AP, Marchais SJ. Pathophysiology of left ventricular hypertrophy in dialysis patients. Blood Purif. 1994;12:277-83.
De Filippi C, Van Kimmenade RR, Pinto YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol. 2008;101:82-88.
Austin WJ, Bhalia V, Hernandez-Arce I, Isakson SR, Boede J, Clopton P et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol. 2006;126:506-12.
Niizuma S, Iwanaga Y, Yahata T, Goto Y, Kita T, Miyazaki S et al. Plasma B-type natriuretic peptide levels reflect the presence and severity of stable coronary artery disease in chronic haemodialysis patients. Nephrol Dial Transplant. 2009;24:597-603.
Toto RD. Anemia of chronic disease: Past, present, and future. Kidney Int. 2003;64 (Suppl 87):S20-S23.
Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009;32:1320-1326.
Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases:from hypothesis to novel therapeutics. Kidney Int. 2008;74:867-872.
Rao M, Pereira BJG. Optimal anemia management reduces cardiovascular morbidity, mortality and costs in chronic kidney disease. Kidney Int. 2005;68:1432-1438.
Schleiffer T, Nagel D, Franz H, Falk M, Valentiner I, Wildburg G et al. Endothelin and atrial natriuretic peptide in non-insulin dependent diabetic versus nondiabetic patients on chronic hemodyalisis. Ren Fail. 1994;16:747-58.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004;15:2186-94.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-92.
López EG, Carrero JJ, Sulivan ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int. 2005;27(Suppl 2):S205-S209.
Mook KH, Song IS, Yang WS, Shin YT, Kin SB, Song JK et al. Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodyalisis patients. Am J Nephrol. 2000;20:396-401.
Wang AY. Prognostic value of C-reactive protein for heart disease in dialysis patients. Curr Opin Investig Drugs. 2005;6:879-86.
Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant. 2001;16:1459-64.
Wang AY, Sanderson J, Sea MM, Wang M, Lam CW, Li PK et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. Am J Clin Nutr. 2003;77:834-41.
Alvarez-Aguilar C, Lara-Romero D, Piñón-Escobedo J, Gómez-García A, Alvarez-Paredes AR. Intima-media thickness is associated with non-traditional risk factors and ischemic heart disease in hemodialysis patients. Ther Apher Dial. 2012;16:104-106.
Sun L, Sun Y, Zhao X, Xu C, Chen D, Li L et al. Predictive role of BNP and NT-pro-BNP in hemodialysis patients. Nephron Clin Pract. 2008;110:178-184.
Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christeensen JH. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol. 2009;71:380-386.
Enlaces refback
- No hay ningún enlace refback.